Pharmaceutical

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.

Apr 17, 2024 - 00:00
MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool

STAT+: ‘We’re getting much more aggressive’: Microsoft’...

Mar 20, 2023

STAT+: Top FDA official: Agency needs to start using accelerated approval for gene therapies

STAT+: Top FDA official: Agency needs to start using ac...

Mar 20, 2023

Bernie Sanders plans more drug price caps as big pharma fights back

Bernie Sanders plans more drug price caps as big pharma...

Jul 29, 2023